RD13-02 cell therapy for relapsed CD7+ NK/T lymphoma
Part of Cancer clinical trials.
This trial uses a new type of immune cell (RD13-02) to treat a rare and aggressive lymphoma that hasn't responded to other treatments. It targets cancer cells that carry a specific marker called CD7.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 70 years old.
- You need a type of lymphoma called relapsed or refractory NK/T lymphoma that has come back or not responded to treatment.
- Your lymphoma cells must have the CD7 protein (a marker on the cell surface).
- Your bone marrow must contain at least 5% abnormal cells (blasts).
- Your kidneys, liver, heart, and overall health must be good enough for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests a new treatment made from your own immune cells (NK cells) that are modified to recognize and attack cancer cells with a marker called CD7. It is for people whose blood cancer has returned or not improved with other treatments.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a new cell therapy called CD7 CAR-T that targets a specific protein on your cancer cells. It is for people with T-cell lymphoma or T-cell leukemia that has not responded to other treatments or has come back.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.